Literature DB >> 21593311

Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family.

Sabina Anwar1, Owen Peters, Steven Millership, Natalia Ninkina, Natalie Doig, Natalie Connor-Robson, Sarah Threlfell, Gurdeep Kooner, Robert M Deacon, David M Bannerman, J Paul Bolam, Sreeganga S Chandra, Stephanie J Cragg, Richard Wade-Martins, Vladimir L Buchman.   

Abstract

The synucleins (α, β, and γ) are highly homologous proteins thought to play a role in regulating neurotransmission and are found abundantly in presynaptic terminals. To overcome functional overlap between synuclein proteins and to understand their role in presynaptic signaling from mesostriatal dopaminergic neurons, we produced mice lacking all three members of the synuclein family. The effect on the mesostriatal system was assessed in adult (4- to 14-month-old) animals using a combination of behavioral, biochemical, histological, and electrochemical techniques. Adult triple-synuclein-null (TKO) mice displayed no overt phenotype and no change in the number of midbrain dopaminergic neurons. TKO mice were hyperactive in novel environments and exhibited elevated evoked release of dopamine in the striatum detected with fast-scan cyclic voltammetry. Elevated dopamine release was specific to the dorsal not ventral striatum and was accompanied by a decrease of dopamine tissue content. We confirmed a normal synaptic ultrastructure and a normal abundance of SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein complexes in the dorsal striatum. Treatment of TKO animals with drugs affecting dopamine metabolism revealed normal rate of synthesis, enhanced turnover, and reduced presynaptic striatal dopamine stores. Our data uniquely reveal the importance of the synuclein proteins in regulating neurotransmitter release from specific populations of midbrain dopamine neurons through mechanisms that differ from those reported in other neurons. The finding that the complete loss of synucleins leads to changes in dopamine handling by presynaptic terminals specifically in those regions preferentially vulnerable in Parkinson's disease may ultimately inform on the selectivity of the disease process.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593311      PMCID: PMC3154647          DOI: 10.1523/JNEUROSCI.6194-10.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  50 in total

1.  Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis.

Authors:  F J Lee; F Liu; Z B Pristupa; H B Niznik
Journal:  FASEB J       Date:  2001-04       Impact factor: 5.191

2.  Attenuation of dopamine transporter activity by alpha-synuclein.

Authors:  Christophe Wersinger; Anita Sidhu
Journal:  Neurosci Lett       Date:  2003-04-17       Impact factor: 3.046

Review 3.  Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses.

Authors:  John Q Trojanowski; Virginia M Y Lee
Journal:  Neurotoxicology       Date:  2002-10       Impact factor: 4.294

4.  Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration.

Authors:  Sreeganga Chandra; Gilbert Gallardo; Rafael Fernández-Chacón; Oliver M Schlüter; Thomas C Südhof
Journal:  Cell       Date:  2005-11-04       Impact factor: 41.582

5.  A role for alpha-synuclein in the regulation of dopamine biosynthesis.

Authors:  Ruth G Perez; Jack C Waymire; Eva Lin; Jen J Liu; Fengli Guo; Michael J Zigmond
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

6.  Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice.

Authors:  Erica L Unger; David J Eve; Xiomara A Perez; Dawn K Reichenbach; Yanqun Xu; Michael K Lee; Anne M Andrews
Journal:  Neurobiol Dis       Date:  2005-10-14       Impact factor: 5.996

7.  Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease.

Authors:  Ikuko Mizuta; Tatsuhiko Tsunoda; Wataru Satake; Yuko Nakabayashi; Masahiko Watanabe; Atsushi Takeda; Kazuko Hasegawa; Kenji Nakashima; Mitsutoshi Yamamoto; Nobutaka Hattori; Miho Murata; Tatsushi Toda
Journal:  Hum Genet       Date:  2008-06-22       Impact factor: 4.132

8.  Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.

Authors:  Darren C Robertson; Oliver Schmidt; Natalia Ninkina; Paul A Jones; John Sharkey; Vladimir L Buchman
Journal:  J Neurochem       Date:  2004-06       Impact factor: 5.372

9.  Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system.

Authors:  V L Buchman; H J Hunter; L G Pinõn; J Thompson; E M Privalova; N N Ninkina; A M Davies
Journal:  J Neurosci       Date:  1998-11-15       Impact factor: 6.167

10.  Genome-wide association study reveals genetic risk underlying Parkinson's disease.

Authors:  Javier Simón-Sánchez; Claudia Schulte; Jose M Bras; Manu Sharma; J Raphael Gibbs; Daniela Berg; Coro Paisan-Ruiz; Peter Lichtner; Sonja W Scholz; Dena G Hernandez; Rejko Krüger; Monica Federoff; Christine Klein; Alison Goate; Joel Perlmutter; Michael Bonin; Michael A Nalls; Thomas Illig; Christian Gieger; Henry Houlden; Michael Steffens; Michael S Okun; Brad A Racette; Mark R Cookson; Kelly D Foote; Hubert H Fernandez; Bryan J Traynor; Stefan Schreiber; Sampath Arepalli; Ryan Zonozi; Katrina Gwinn; Marcel van der Brug; Grisel Lopez; Stephen J Chanock; Arthur Schatzkin; Yikyung Park; Albert Hollenbeck; Jianjun Gao; Xuemei Huang; Nick W Wood; Delia Lorenz; Günther Deuschl; Honglei Chen; Olaf Riess; John A Hardy; Andrew B Singleton; Thomas Gasser
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

View more
  88 in total

1.  Impaired spatial and working memory in ageing mice with targeted inactivation of α-synuclein gene.

Authors:  V S Kokhan; G I Van'kin; N N Ninkina; T A Shelkovnikova; S O Bachurin
Journal:  Dokl Biol Sci       Date:  2012-01-07

Review 2.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

Review 3.  Dynamic structural flexibility of α-synuclein.

Authors:  Danielle E Mor; Scott E Ugras; Malcolm J Daniels; Harry Ischiropoulos
Journal:  Neurobiol Dis       Date:  2015-12-31       Impact factor: 5.996

4.  Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons.

Authors:  Martin Lundblad; Mickael Decressac; Bengt Mattsson; Anders Björklund
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

Review 5.  The physiological role of α-synuclein and its relationship to Parkinson's Disease.

Authors:  David Sulzer; Robert H Edwards
Journal:  J Neurochem       Date:  2019-07-28       Impact factor: 5.372

6.  Alpha-synuclein deletion decreases motor impulsivity but does not affect risky decision making in a mouse Gambling Task.

Authors:  Yolanda Peña-Oliver; Sandra Sanchez-Roige; David N Stephens; Tamzin L Ripley
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

Review 7.  Cell Biology and Pathophysiology of α-Synuclein.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

8.  Showing transmitters the door: synucleins accelerate vesicle release.

Authors:  Dennis J Selkoe
Journal:  Nat Neurosci       Date:  2017-04-25       Impact factor: 24.884

Review 9.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Authors:  Kelly M Lohr; Shababa T Masoud; Ali Salahpour; Gary W Miller
Journal:  Eur J Neurosci       Date:  2016-09-02       Impact factor: 3.386

10.  α-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers.

Authors:  David C DeWitt; Elizabeth Rhoades
Journal:  Biochemistry       Date:  2013-03-27       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.